How do you utilize JAK inhibitors for alopecia in the pediatric population?

There is little difference about counseling between adolescents (lowest age group approved) and adults, but the greater concern is really understanding the risks, especially given that the lifetime duration on the medication is likely going to be longer in an adolescent vs an adult -- and we know th...

In the pediatric population, JAK inhibitors can be an appropriate treatment for alopecia areata, and ritlecitinib is approved for adolescents 12 years and older. Counseling on the use of JAK inhibitors requires an in-depth conversation about potential risks, including those identified by the FDA in ...